How does TB-500 work?

This site's TB-500 profile defines the substance as the N-acetylated thymosin beta-4 fragment 17 to 23, sequence Ac-LKKTETQ. The hypothesis is that the LKKTET sequence binds monomeric G-actin the way the parent peptide does. FDA's 2026 review found no published study giving this fragment to a person by any route, no human pharmacokinetic data, and no FAERS reports through March 26, 2025. The review also notes that wound-healing work was done mostly with the non-acetylated heptapeptide or with the full parent peptide, and those results cannot be extrapolated directly to the acetylated fragment sold as TB-500. The first registered trial of the fragment, NCT07487363, is recruiting. This FAQ does not invent a human mechanism from a parent peptide. Full record at /compounds/tb-500.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of healing and recovery peptides. BPC-157, TB-500, GHK-Cu, and the tissue repair family, including what actually has human data.